~/ The therapeutic application of barbiturate-induced coma was evaluated in a primate model of focal cerebral ischemia. A standardized regimen of pentobarbital was used, and the times of initiation of administration were varied following a 6-hour middle cerebral artery occlusion in baboons. Three groups of five animals were treated at 30, 120, and 240 minutes after occlusion, while one group of five animals received no barbiturate therapy. Complete protection from intracranial pressure (ICP) elevation and iscbemic damage was seen only in the group treated at 30 minutes. Those treated at 120 minutes, while doing better than untreated animals, still had ICP elevation and a marked neuropathological deficit. Animals treated at 240 minutes suffered a detrimental effect, in that malignant ICP and marked ischemic damage occurred earlier than in the untreated animals. The safe "therapeutic window" for barbiturateinduced coma in this animal model does not extend beyond 2 hours. Delayed administration results in a deleterious response and not merely a lack of protection.
S
EVERAL investigations have demonstrated a protective effect of barbiturates in the therapy of experimental focal cerebral ischemia. 1~ We have previously examined barbiturate therapy in permanent and temporary middle cerebral artery (MCA) occlusion. The use of barbiturates in permanent occlusion was associated with a deleterious response, whereas the initiation of therapy at 30 minutes after temporary occlusion resulted in nearly complete protection, z2 In order to further define the limits of barbiturate protection, we have analyzed the effect of increasing the time between the onset of a 6-hour ischemic insult and barbiturate administration. The results of these studies are the basis of the present report.
Materials and Methods

For this study, 20 male baboons (Papio anibus)
were randomly assigned to one of the following groups:
Group I: 6 hours occlusion, no treatment Group II: 6 hours occlusion, barbiturates administered after a 30-minute delay Group III: 6 hours occlusion, barbiturates administered after a 2-hour delay Group IV: 6 hours occlusion, barbiturates administered after a 4-hour delay. All animals were prepared for experimentation as follows. Animals were anesthetized with ketamine HCI. An inflatable balloon occluder was placed around the MCA by way of a transorbital approach. 27,2s The cuff was positioned just distal to the origin of the MCA and proximal to the origin of the lenticulostriate branches.
After occluder implantation, the animals were prepared for intensive-care monitoring. Percutaneous femoral catheterization was employed to introduce long and short arterial lines, and two central venous lines. A fiberoptic epidural sensor was positioned through a right parietal trephine for intracranial pressure (ICP) monitoring. Two sets of symmetrically placed (frontal, occipital, ear-lobe) electroencephalo- 1  32  292  115  36  70  38  101  63  12  33  308  110  36  107  30  26  5  1.3  34  285  105  35  70  39  150+  1.4  33  305  120  36  90  34  150+  1.5  33  302  110  36  103  35  29  17   II.1  35  300  100  90  37  130  32  165  40  14  11.2  35  295  115  100  36  125  33  240  30  10  11.3  36  305  100  100  37  150  35  180  35 graphic (EEG) needle electrodes were fixed to the scalp. A rectal probe was inserted for temperature monitoring. A urinary catheter was inserted for measurement of urinary output and specific gravity determinations.
All animals were placed in a primate restraint chair and allowed to recover for at least 24 hours after implantation before subsequent experimentation to ensure that no neurological deficit had occurred secondary to surgery. All animalS were awake and free from the effects of anesthetics at the time of occlusion. Those animals which served as controls underwent MCA occlusion for 6 hours and were maintained in the primate restraint chair. Monitoring was conducted for 96 hours.
Barbiturate-treated animals underwent MCA occlusion in the same manner as control animals. Pentobarbital was used as the anesthetic agent in all animals. Therapy was instituted at either 30, 120, or 240 minutes after occlusion. A loading dose of 30 nag/ kg was administered by slow intravenous infusion. Continuous barbiturate infusion was then begun and titrated to maintain an isoelectric EEG (less than 2 gV potentials) while not allowing a reduction of mean arterial blood pressure of more than 15%. 21 Aramine (metaraminol HC1) was administered for the occasional periods of hypotension that could not be controlled by decreasing the barbiturate infusion. The treated animals were intubated and ventilated to maintain normocarbia (pCO2 32 to 38 torr) and normoxia (pO2 90 to 120 torr). All treated animals were maintained in barbiturate coma for 96 hours. Barbiturates were then discontinued.
After the period of intensive-care observation, all surviving animals were returned to the Department of Animal Facilities and observed in their cages. Final neurological examination was performed 1 week after occlusion by an examiner unaware of the animals' history. Neurological examination was based on a 100-point scale which allowed evaluation of unrestrained primates. Lower scores represented worse outcomes.
The animals were humanely killed 1 week after occlusion with intravenous KC1, and the brains removed and suspended in 10% buffered formalin for 1 week. Neuropathological examination was performed by an examiner unaware of the animals' history. Pathological examination was based on a 100-point scale to evaluate the percentage of grossly infarcted hemisphere, the presence of gross shift of midline structures, and the microscopic appearance of the neural tissue and microvasculature. Lower scores represented worse outcome.
The brains of those animals that died before the end of intensive-care monitoring were removed immediately and analyzed as above. In those treated animals that developed malignant ICP (hypertension greater than the blood pressure for 6 hours), the barbiturate infusion was discontinued, and the animals were observed for 24 hours. An isoelectric EEG for this time period was considered evidence of brain death. The brains were then removed and analyzed as described above.
Results Physiological monitoring parameters, including blood pressure, heart rate, pO2, pCO2, and temperature were similar in all groups ( Table 1) . The results of the neurological outcome and pathological evaluation are summarized in Table 2 and Fig. 1 .
Untreated animals with 6 hours of MCA occlusion (Group I) had a high incidence of malignant intracranial hypertension and poor neurological scores among survivors. Two animals (Nos. 1.2 and 1.4) died within 48 hours from aggravated intracranial hypertension. The terminal event of cardiac and respiratory arrest occurred only after prolonged ICP elevation. Three animals survived; two (Nos. I. 1 and 1.3) in a vegetative state with raised ICP, and the third with a profound hemiplegia. Neuropathological evaluation confirmed the presence of massive cerebral edema in those animals with raised ICP.
In contrast, Group II animals, with treatment 30 minutes after 6 hours of MCA occlusion, all did well. There were no deaths attributable to malignant ICP (Figs. 2 and 3) . Neuropathologicalevaluation revealed only minimal neuronal changes, but no gross midline shift or other evidence of brain tissue destruction.
In Group III animals, with treatment 2 hours after 6 hours of MCA occlusion, the results were varied. Table 1 ) and evidence of a complete hemiplegia (average neurological score 47). Group IV animals, in which treatment was initiated 4 hours after 6 hours of MCA occlusion, all did poorly. Three animals (Nos. IV.l, IV.2, and IV.5) died of malignant intracranial hypertension which developed within 6 to 12 hours (Figs. 2 and 3 ). Neuropathological evaluation was consistent with massive cerebral edema and extensive infarction (Fig. 4) . One animal (No. IV.3) died of malignant intracranial hypertension that commenced immediately upon withdrawal of barbiturate therapy. The remaining animal had a sustained ICP elevation and a severe hemiplegia with markedly lethargic behavior.
Discussion
The limits of barbiturate protection in focal cerebral ischemia have not been well defined. This situation results in part from the difficulty in comparing the nature of varying ischemic lesions in different species and differing methods of barbiturate administration. We have maintained a standard ischemic lesion and barbiturate treatment regimen while altering only the presence or absence of recirculation and the timing of initiation of therapy with respect to the onset of occlusion. Barbiturate protection in our series has been dependent on recirculation. 22 As indicated by the present series, recirculation is only a necessary condition, and not a sufficient condition for barbiturate protection. This protective effect is markedly dependent on the timing of initiation of therapy with respect to the onset of ischemia. The dependence of protection on timing of therapy is reflected both in the neurological and pathological scores and in the ICP response (Figs. 2 and 3) .
Barbiturate therapy provided nearly complete protection when initiated 30 minutes after the onset of the 6-hour occlusion. Barbiturate therapy given 2 hours after the onset of ischemia was associated with less complete protection. The average neurological score of 50 in this group represents a major hemiparesis. Similarly, neuropathological correlation revealed evidence of edema and neuronal destruction. That some protective effect was afforded from barbiturate administration at 2 hours is evident from a comparison of this response with the average neurological and pathological outcome in the natural history of reperfusion at 6 hours. Here, massive cerebral edema and death was the inevitable outcome in our series. Other investigators have reported a similar aggravation of edema and hemorrhagic infarction with reperfusion, whether by embolectomy or by an extracranial-intracranial bypass procedure, when performed more than 5 hours from the onset of ischemia.7,s, 11
Barbiturate therapy initiated 4 hours after the onset of ischemia was associated not merely with a lack of protection, but actually resulted in a deterioration as compared to the untreated group. In this group, malignant ICP elevation appeared in the majority of animals earlier than in the untreated group.
In a previous study, Corkill, et al., 2 examined the effect of timing of therapy on the degree of barbiturate protection. In their model of MCA occlusion in dogs, no protection from ischemic damage was evident when barbiturate therapy was initiated more than 1 hour after the onset ofischemia. In their study, singledose barbiturate therapy of 40 mg/kg was administered intramuscularly. Our series indicates that larger doses and more prolonged barbiturate administration does allow extension of barbiturate protection. Furthermore, in contrast to the findings of Corkill, et al., we noted a deleterious effect when barbiturate administration was delayed 4 hours.
Our data suggest the existence of a temporal "therapeutic window" during which period barbiturate treatment is protective, and after which barbiturate administration can be harmful (Fig. 4) . The factors responsible for such a response must at this point remain conjectural. Previous work by Hoff, et al., 1~ has shown greater protection from focal ischemia with larger barbiturate doses. The maximum amount of protection may be obtained at that dose which yields the maximum anesthetic effect, or an isoelectric EEG. 29,a~ Furthermore, since barbiturate protection appears to be associated with a decrease of ischemic edema, 2s,26 the greatest protection should be obtained from therapy that extends throughout the period of maximum ischemic edema, that is, up to 96 hours after the ischemic insult. 17,ts These principles were incorporated into our regimen of barbiturate administration. That such a regimen may be effective in early administration, not effective in intermediate administration, and deleterious in delayed administration may be explained in part by circulatory and biochemical considerations.
Recent investigation has stressed the role of free radical and free fatty acid interaction with membrane lipids in mediating ischemic damage. Similarly, one postulated mechanism of barbiturate protection has been inhibition of the formation of free radicals and endoperoxidation of fatty acids. 1,4-6,14,19,23,31 It has previously been demonstrated that microcirculatory collapse after focal cerebral ischemia occurs within 2 hours of occlusion? In order to be effective, it may be that barbiturate delivery to an ischemic focus is critical. Barbiturate distribution, at least initially, is related to regional cerebral blood flow. 24 If barbiturate action is dependent on barbiturate delivery to the area of ischemia, then the failure of protection after 2 hours may be explained in part on this basis.
In addition to decreasing the generation of free fatty acids during ischemia, barbiturates may also delay their clearance. If the clearance of such compounds is impaired, their continued presence could produce greater cellular damage. The initiation of barbiturate therapy after 4 hours may serve only to impair elimination of membrane-damaging compounds and thereby produce earlier and more profound destruction than in untreated animals. The ICP tracings of Group III and Group IV animals reflect such an earlier demise (Fig. 3) .
Whether a combination of different therapeutic regimens can provide enhanced protection or extend the limits of barbiturate therapy must be determined. 2~ Yonas, et al., 32 have studied different barbiturates and suggested that thiobarbiturates, which have greater solubility, may permit more barbiturate to reach a region ofischemia. In light of the possible detrimental effects of barbiturate therapy, it would be particularly important to know if some less toxic therapy with some effect against focal cerebral ischemia could be administered as a temporizing measure. It may be possible that agents which maintain the microcirculation, such as osmotic agents 12,~3 or imidazole derivatives which block prostaglandin but not prostacyclin action, 9 may safely permit delayed barbiturate delivery to an ischemic focus.
